Recorded last week at Fierce Biotech Week in Boston, this episode of “The Top Line” features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge Labs.

In a conversation with Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, Fortney discusses the company’s decade-long effort to use human aging data to identify drug targets tied to longevity and age-related disease. She also breaks down BioAge’s oral NLRP3 inhibitor, BGE-102, which the company believes could have applications across cardiovascular, ocular and CNS diseases by targeting inflammation linked to aging biology.

The conversation also explores why pharma companies are paying closer attention to aging and exercise biology, how GLP-1 drugs are reshaping conversations around prevention and what the future of aging-related medicine could look like.

To learn more about the topics in this episode: 
BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS
Novartis, BioAge take on age-related diseases in $550M pact
What can we learn from 2024’s biotech IPOs?

Recorded last week at Fierce Biotech Week in Boston, this episode of &ldquo;The Top Line&rdquo; features a conversation with Kristen Fortney, Ph.D., co-founder and CEO of BioAge Labs.
In a conversation with Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, Fortney discusses the company&rsquo;s decade-long effort to use human aging data to identify drug targets tied to longevity and age-related disease. She also breaks down BioAge&rsquo;s oral NLRP3 inhibitor, BGE-102, which the company believes could have applications across cardiovascular, ocular and CNS diseases by targeting inflammation linked to aging biology.
The conversation also explores why pharma companies are paying closer attention to aging and exercise biology, how GLP-1 drugs are reshaping conversations around prevention and what the future of aging-related medicine could look like.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/ceo-bioages-triple-threat-drug-aims-treat-cardiovascular-ocular-and-cns-disease">BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/novartis-and-bioage-take-age-related-diseases-new-550m-pact">Novartis, BioAge take on age-related diseases in $550M pact</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/what-can-we-learn-2024s-biotech-ipos">What can we learn from 2024&rsquo;s biotech IPOs?</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;